EHF-Imprinted Autologous Blood-Fraction Blank Granules and Biological-Parameter Improvement in Cancer-Remission Patients and Healthy Adults: A 12-Week Prospective Controlled Exploratory Study

Abstract

Background: Patients with cancer may experience persistent fatigue, anemia tendency, immune depletion, inflammatory activation, metabolic stress, and reduced autonomic resilience after conventional treatment. Patient-specific blank granules prepared from autologous biological material are used in selected traditional, homeopathic, and subtle-field practices, but controlled supportive-care data remain limited.

Objective: To evaluate whether blank granules imprinted ex vivo with autologous blood-fraction information using an extremely high frequency (EHF) millimeter-wave device were associated with biological-parameter improvement in cancer-remission patients and healthy adults.

Methods: This 12-week prospective controlled exploratory study enrolled 72 adults with cancer in clinical remission and 120 healthy adults. The cancerremission active group included 36 participants (21 women/15 men; age 55 +/- 6 years), the cancer-remission control group included 36 participants (20 women/16 men; age 53 +/- 7 years), and the healthy active cohort included 120 participants (54 women/66 men; age 58 +/- 7 years). Participants originated from Turkiye, the United Kingdom, the United States, the Netherlands, Jordan, the United Arab Emirates, and Qatar. Cancer participants were allocated 1:1 to EHF-imprinted autologous blood-fraction blank granules or matched control blank granules. Healthy adults received EHF-imprinted autologous blood-fraction blank granules and followed the same assessment schedule.

Results: Compared with matched control blank granules, the active cancer-remission group showed greater 12-week improvement in hemoglobin, red blood cell count, red-cell distribution width, lymphocytes, natural killer cells, T4/T8 ratio, exploratory PrimedMT-cell percentage, C-reactive protein, fibrinogen, albumin-globulin ratio, heart-rate variability, sleep, and fatigue. Full-parameter response occurred in 16 of 36 active cancer participants and 5 of 36 control participants. Healthy adults showed favorable Week 12 aggregate shifts across immune-surveillance, inflammatory, metabolic, autonomic, sleep, and fatigue parameters; all 120 met the predefined healthy-cohort full-response criterion. Relative biological movement was generally larger in the cancer-remission active group than in healthy adults, consistent with greater baseline dysregulation and a larger recovery window. No adverse events were observed.

Conclusion: EHF-imprinted autologous blood-fraction blank granules were associated with greater supportive biological-parameter improvement than
matched control granules in cancer-remission patients and favorable aggregate shifts in healthy adults. The study did not assess tumor  response, progressionfree survival, or overall survival.